131 related articles for article (PubMed ID: 36669975)
21. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
22. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer.
Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C
Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905
[TBL] [Abstract][Full Text] [Related]
23. Role of pICLn in methylation of Sm proteins by PRMT5.
Pesiridis GS; Diamond E; Van Duyne GD
J Biol Chem; 2009 Aug; 284(32):21347-59. PubMed ID: 19520849
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
[TBL] [Abstract][Full Text] [Related]
25. Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A.
Sakai N; Saito Y; Fujiwara Y; Shiraki T; Imanishi Y; Koshimizu TA; Shibata K
Biochem Biophys Res Commun; 2015 Nov; 467(4):778-84. PubMed ID: 26482848
[TBL] [Abstract][Full Text] [Related]
26. Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods.
Zhu K; Jiang CS; Hu J; Liu X; Yan X; Tao H; Luo C; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):721-727. PubMed ID: 29154828
[TBL] [Abstract][Full Text] [Related]
27. Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2
Ichikawa T; Shanab O; Nakahata S; Shimosaki S; Manachai N; Ono M; Iha H; Shimoda K; Morishita K
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118615. PubMed ID: 31765670
[TBL] [Abstract][Full Text] [Related]
28. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
29. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Jain K; Jin CY; Clarke SG
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10101-10106. PubMed ID: 28874563
[TBL] [Abstract][Full Text] [Related]
31. Methylosome Protein 50 and PKCδ/p38δ Protein Signaling Control Keratinocyte Proliferation via Opposing Effects on p21Cip1 Gene Expression.
Saha K; Eckert RL
J Biol Chem; 2015 May; 290(21):13521-30. PubMed ID: 25851901
[TBL] [Abstract][Full Text] [Related]
32. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Gullà A; Hideshima T; Bianchi G; Fulciniti M; Kemal Samur M; Qi J; Tai YT; Harada T; Morelli E; Amodio N; Carrasco R; Tagliaferri P; Munshi NC; Tassone P; Anderson KC
Leukemia; 2018 Apr; 32(4):996-1002. PubMed ID: 29158558
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2
Ichikawa T; Suekane A; Nakahata S; Iha H; Shimoda K; Murakami T; Morishita K
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474089
[TBL] [Abstract][Full Text] [Related]
34. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5.
Chen M; Yi B; Sun J
J Biol Chem; 2014 Aug; 289(35):24325-35. PubMed ID: 25012667
[TBL] [Abstract][Full Text] [Related]
36. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
37. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
[TBL] [Abstract][Full Text] [Related]
38. Unique Features of Human Protein Arginine Methyltransferase 9 (PRMT9) and Its Substrate RNA Splicing Factor SF3B2.
Hadjikyriacou A; Yang Y; Espejo A; Bedford MT; Clarke SG
J Biol Chem; 2015 Jul; 290(27):16723-43. PubMed ID: 25979344
[TBL] [Abstract][Full Text] [Related]
39. Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Gu Z; Li Y; Lee P; Liu T; Wan C; Wang Z
PLoS One; 2012; 7(8):e44033. PubMed ID: 22952863
[TBL] [Abstract][Full Text] [Related]
40. Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
Musiani D; Bok J; Massignani E; Wu L; Tabaglio T; Ippolito MR; Cuomo A; Ozbek U; Zorgati H; Ghoshdastider U; Robinson RC; Guccione E; Bonaldi T
Sci Signal; 2019 Apr; 12(575):. PubMed ID: 30940768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
